...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Bone marrow transplantation >Pre-transplant use of tyrosine kinase inhibitors and transplant associated thrombotic microangiopathy-a single centre analysis of incidence, risk factors and outcomes
【24h】

Pre-transplant use of tyrosine kinase inhibitors and transplant associated thrombotic microangiopathy-a single centre analysis of incidence, risk factors and outcomes

机译：移植前使用酪氨酸激酶抑制剂和移植相关血栓性微盲疗 - 一种入射，危险因素和结果的单一中心分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Transplant associated thrombotic microangiopathy (TA-TMA) is life-threatening complication post allogeneic stem cell transplant (ASCT). Risk factors and prognosis of TA-TMA are not well defined. We retrospectively studied consecutive ASCT patients with AML, ALL, and CML from January 2008 to March 2019 to study the incidence, risk factors, and outcomes of TMA. Definitive and probable TA-TMA was defined using Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) and Cho criteria, respectively. Risk factors explored were age, gender, diagnosis, type of transplant, use of tyrosine kinase inhibitors (TKI) pre transplant, conditioning regimen, and acute GVHD. Standard statistical methods were used. Total 241 patients, 179 (74.2 %) males, median age of 29 years were studied. Diagnoses were AML in 104, ALL in 85 (Ph+ve 23) and CML 52. Total 26 (10.7%) patients (22 males) developed TA-TMA at median of day+102. On multivariate analysis, pre-HSCT TKI (OR 2.7, p = 0.028), haplo-HSCT (OR 3.16, p = 0.018) and presence of acute GVHD (OR 4.17, p = 0.003) were significant risk factors. With a median follow up of 60 months, median OS with and without TA-TMA was 18 and 97 months respectively (p = 0.021). The association of pre-HSCT with TKI with TA-TMA merits further exploration in prospective studies.
机译：移植相关的血栓性微盲（TA-TMA）是同种异体干细胞移植后生命危及生命的并发症（ASCT）。 TA-TMA的危险因素和预后没有明确定义。我们回顾性地研究了2008年1月至2019年3月至2019年3月的AML，全部和CML的连续asct患者，以研究TMA的发病率，危险因素和结果。使用血液和骨髓移植临床试验网络（BMT-CTN）和CHO标准定义了最终和可能的TA-TMA。探索的危险因素是年龄，性别，诊断，移植型，使用酪氨酸激酶抑制剂（TKI）预移植，调理方案和急性GVHD。使用标准统计方法。研究总计241名患者，179名（74.2％）男性，中位年龄29岁。诊断为104中的AML，全部为85（pH + ve 23）和CML 52.总计26例（10.7％）患者（22名男性）在日间+ 102的中位开发TA-TMA。在多变量分析中，HSCT TKI（或2.7，P = 0.028），HAPLO-HSCT（或3.16，P = 0.018）和急性GVHD（或4.17，P = 0.003）的存在是显着的风险因素。中位于60个月的中位数，分别为18和97个月的中位OS分别为18和97个月（P = 0.021）。 HSCT与TKI与TA-TMA的协会在前瞻性研究中进一步探索。

著录项

  • 来源
    《Bone marrow transplantation》 |2021年第7期|共5页
  • 作者

    Punatar Sachin; Kalantri Siddhesh A.; Chichra Akanksha; Agrawal Amit Kumar; Nayak Lingaraj; Bonda Avinash; Gokarn Anant; Bagal Bhausaheb; Mathew Libin; Kannan Sadhana; Khattry Navin;

  • 作者单位

    ACTREC Tata Mem Ctr Dept Med Oncol HSCT Unit Kharghar 410210 Navi Mumbai India;

    ACTREC Tata Mem Ctr Dept Med Oncol HSCT Unit Kharghar 410210 Navi Mumbai India;

    ACTREC Tata Mem Ctr Dept Med Oncol HSCT Unit Kharghar 410210 Navi Mumbai India;

    ACTREC Tata Mem Ctr Dept Med Oncol HSCT Unit Kharghar 410210 Navi Mumbai India;

    ACTREC Tata Mem Ctr Dept Med Oncol HSCT Unit Kharghar 410210 Navi Mumbai India;

    ACTREC Tata Mem Ctr Dept Med Oncol HSCT Unit Kharghar 410210 Navi Mumbai India;

    ACTREC Tata Mem Ctr Dept Med Oncol HSCT Unit Kharghar 410210 Navi Mumbai India;

    ACTREC Tata Mem Ctr Dept Med Oncol HSCT Unit Kharghar 410210 Navi Mumbai India;

    ACTREC Tata Mem Ctr Dept Med Oncol HSCT Unit Kharghar 410210 Navi Mumbai India;

    ACTREC Tata Mem Ctr Dept Biostat Paymaster Shodhika Kharghar 410210 Navi Mumbai India;

    ACTREC Tata Mem Ctr Dept Med Oncol HSCT Unit Kharghar 410210 Navi Mumbai India;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 治疗学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号